Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
Anaplastic lymphoma kinase fusion gene-positive (ALK+) disease occurs in approximately 5% of patients with advanced non-small-cell lung cancer (NSCLC) [1]. Current standard first-line therapy for patients with advanced stage ALK+ NSCLC is an ALK inhibitor, such as crizotinib, ceritinib, brigatinib, or alectinib [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Maurice P érol, Nick Pavlakis, Evgeny Levchenko, Marco Platania, Julio Oliveira, Silvia Novello, Rita Chiari, Teresa Moran, Emmanuel Mitry, Eveline Nüesch, Ting Liu, Bogdana Balas, Krzysztof Konopa, Solange Peters Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Study